Skip to main content
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

view all Clinical Trials

Overview

To investigate effects of SAR440340 (anti-interleukin-33 [IL‑33] monoclonal antibody [mAb]) compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over up to 52 weeks of treatment.

Contact

For more information about this trial or to inquire about eligibility, email breathe@temple.edu